Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
CCCC Stock Chart & Stats
$2.48
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.48
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.09 - $5.62
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.30M
Market Cap
$226.78M
Enterprise Value$30.67M
Total Cash (Recent Filing)$191.88M
Total Debt (Recent Filing)$61.46M
Price to Earnings (P/E)―
Beta3.46
Next Earnings
Feb 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding96,914,420
10 Day Avg. Volume1,232,890
30 Day Avg. Volume2,303,801
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.16
Price to Sales (P/S)7.02
P/FCF Ratio-3.82
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.08
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$8.50Price Target Upside242.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Collaborative ValidationCCCC’s collaborations with Roche, Biogen, and Merck, all leveraging the TORPEDO platform, provide incremental validation of the Company’s TPD approach.
Drug ApprovalC4 Therapeutics is in discussions with regulators regarding accelerated approval based on a new Ph2 trial.
Therapeutic AdvancesCemsidomide offers a broader therapeutic dosing window in multiple myeloma relative to emerging competitors.
Bears Say
Market CompetitionMM remains a highly competitive category, which could pose challenges for market penetration.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.08 and its highest was $5.62 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $226.78M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 97 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.406 by -$0.034.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 96,914,420 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.406. Following the earnings report the stock price went up 0.422%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
C4 Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (242.74% Upside)
$8.50 (242.74% Upside)
Blogger Sentiment
Neutral
CCCC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 20.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 28.6%
Last 30 Days ▲ 28.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.82%
12-Months-Change
Fundamentals
Return on Equity
-59.98%
Trailing 12-Months
Asset Growth
-29.40%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$8.50
▲(242.74% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.26% Insiders
13.58% Mutual Funds
45.82% Other Institutional Investors
32.50% Public Companies and
Individual Investors